StockNews.AI
IDYA
StockNews.AI
113 days

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

1. IDEAYA Biosciences announced participation in key investor relations events. 2. Events include Barclays Catalyst Calls on May 8, 2025, and RBC Conference on May 20, 2025. 3. Fireside chats will feature CEO Yujiro Hata discussing company advancements. 4. Webcasts of the events will be available on IDEAYA's investor website. 5. IDEAYA focuses on targeted therapeutics in precision medicine and synthetic lethality.

5m saved
Insight
Article

FAQ

Why Bullish?

Investor engagement can enhance visibility and attract potential investors. Historical events suggest similar uplifts when companies present at major conferences.

How important is it?

Increased visibility and investor interest during events likely lead to price fluctuations. Attendance suggests confidence in growth prospects, likely valued by the market.

Why Short Term?

Upcoming events are likely to generate immediate interest and potential short-term stock movement. Similar past events have produced quick reactions in share price.

Related Companies

BAYRYREGNGILD
, /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1'sThursday, May 8th, 2025 at 11:00 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst 2025 RBC Capital Markets Global Healthcare ConferenceTuesday, May 20th, 2025 at 8:30 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research Analyst A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.  Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025. Investor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoChief Accounting Officer[email protected] SOURCE IDEAYA Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News